Market Overview:
The global enteric disease testing market size reached US$ 4.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 5.0 Billion by 2028, exhibiting a growth rate (CAGR) of 3.4% during 2023-2028.
Report Attribute
|
Key Statistics
|
Base Year
|
2022
|
Forecast Years
|
2023-2028
|
Historical Years
|
2017-2022
|
Enteric Disease Testing Market Size in 2022 |
US$ 4.0 Billion |
Enteric Disease Testing Market Forecast in 2028 |
US$ 5.0 Billion |
Enteric Disease Testing Market Growth Rate 2023-2028 |
3.4% |
Enteric diseases are caused by the entering of microorganisms, such as viruses, bacteria and parasites, in the body through the mouth. These pathogens can be acquired through contaminated food and water or by encountering feces of an animal or infected person. The common symptoms of enteric diseases are abdominal cramps, vomiting, nausea and anorexia that can lead to loss of fluids and essential nutrients from the body. In recent years, advancements in diagnostic technologies have revolutionized enteric disease testing and significantly increased the detection rates in symptomatic individuals.
.webp)
The improper drainage and sanitation systems, unsafe drinking water and unhygienic living conditions can significantly increase the risk of enteric diseases. This, along with a substantial rise in medical tourism in recent years, represents one of the key factors impelling the market growth. Besides this, the increasing awareness among individuals about the benefits of early diagnosis is acting as another major growth-inducing factor. Apart from this, several international agencies, such as the World Health Organization (WHO) and the United Nations Children's Fund (UNICEF), are conducting awareness programs and setting up healthcare camps in different countries to promote the testing of enteric diseases. Moreover, several key players are focusing on the commercialization of novel testing technologies, which is contributing to the market growth. Furthermore, as human coronaviruses cases are associated with enteric diseases, several healthcare institutes are conducting studies to find interrelation between enteric disease and the coronavirus disease (COVID-19).
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global enteric disease testing market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product type, technique, disease type and end user.
Breakup by Product Type:
- Reagents and Consumables
- Equipment
Breakup by Technique:
- Molecular Diagnostics
- Immunodiagnostics
Breakup by Disease Type:
- Bacterial Enteric Disease
- C. Difficile
- Campylobacteriosis
- Cholera
- E. Coli
- H. Pylori
- Salmonellosis
- Shigellosis
- Viral Enteric Disease
- Rotavirus
- Norovirus
- Others
- Parasitic Enteric Disease
- Amebiasis
- Cryptosporidiosis
- Giardiasis
Breakup by End User:
- Hospital Diagnostic Laboratories
- Independent Diagnostic Laboratories
- Academic and Research Institutes
- Others
Breakup by Region:
- North America
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, BD (Becton, Dickinson and Company), Bio-Rad Laboratories Inc., Biomerica Inc., Biomérieux SA, Cepheid Inc. (Danaher Corporation), Coris BioConcept, DiaSorin, Meridian Bioscience Inc. and Quest Diagnostics.
Report Coverage:
Report Features |
Details |
Base Year of the Analysis |
2022 |
Historical Period |
2017-2022 |
Forecast Period |
2023-2028 |
Units |
US$ Billion |
Segment Coverage |
Product Type, Technique, Disease Type, End User, Region |
Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered |
Abbott Laboratories, BD (Becton, Dickinson and Company), Bio-Rad Laboratories Inc., Biomerica Inc., Biomérieux SA, Cepheid Inc. (Danaher Corporation), Coris BioConcept, DiaSorin, Meridian Bioscience Inc. and Quest Diagnostics |
Customization Scope |
10% Free Customization |
Report Price and Purchase Option |
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499 |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
- How has the global enteric disease testing market performed so far and how will it perform in the coming years?
- What are the key regional markets?
- What has been the impact of COVID-19 on the global enteric disease testing market?
- What is the breakup of the market based on the product type?
- What is the breakup of the market based on the technique?
- What is the breakup of the market based on the disease type?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global enteric disease testing market and who are the key players?
- What is the degree of competition in the industry?